Current Affairs 2024 POTUS race

Status
Not open for further replies.
The USA was founded by Christopher Columbus in 1492 when he sailed to Corpus Christie TX to find silk and vanilla beans, and that's what led to the USA fighting for independence from Spain. The constitution was written by Abraham Lincoln who, along with Francis Scott Key, penned the Bill of Rights, which states that US citizens do not need to pay taxes. Africa is a country, and so is Paris.
Points deduction for cut and paste from Prager University.
 
Vivek doesn’t think that Martin Shkreli should have been convicted of anything, which should tell anyone all they wanted to know about him.
I saw a comment about him this morning that he comes across as the most online right winger on the stage, which basically means he will blow with the wind of the GOPs most extreme views, which in turn makes him an extremely ugly individual.
 
Vivek doesn’t think that Martin Shkreli should have been convicted of anything, which should tell anyone all they wanted to know about him.
All you need to know about him

In 2015, Ramaswamy raised $360 million for the Roivant subsidiary Axovant Sciences in an attempt to market intepirdine as a drug for Alzheimer's disease.[31][39] In December 2014,[40] Axovant purchased the patent for intepirdine from GlaxoSmithKline (where the drug had failed four previous clinical trials) for $5 million, a small sum in the industry.[32] Ramaswamy appeared on the cover of Forbes in 2015, and said his company would "be the highest return on investment endeavor ever taken up in the pharmaceutical industry."[32][39] Before new clinical trials began, he engineered an initial public offering (IPO) in Axovant.[32] Axovant became a "Wall Street darling" and raised $315 million in its IPO.[40] The company's market value initially soared to almost $3 billion, although at the time it only had eight employees, including Ramaswamy's brother and mother.[32] Ramaswamy took a massive payout after selling a portion of his shares in Roivant to Viking Global Investors.[32] He claimed more than $37 million in capital gains in tax year 2015.[32] Ramaswamy said his company would be the "Berkshire Hathaway of drug development"[3] and touted the drug as a "tremendous" opportunity that "could help millions" of patients, prompting some criticism that he was overpromising.[32]

In September 2017, the company announced that intepirdine had failed in its large clinical trial.[32][41] The company's value plunged; it lost 75% in one day and continued to decline afterward.[32] Shareholders who lost money included various institutional investors, such as the California State Teachers' Retirement System pension fund.[32] Ramaswamy was insulated from much of Axovant's losses because he held his stake through Roivant.[32][40] The company abandoned intepirdine.
 
All you need to know about him

In 2015, Ramaswamy raised $360 million for the Roivant subsidiary Axovant Sciences in an attempt to market intepirdine as a drug for Alzheimer's disease.[31][39] In December 2014,[40] Axovant purchased the patent for intepirdine from GlaxoSmithKline (where the drug had failed four previous clinical trials) for $5 million, a small sum in the industry.[32] Ramaswamy appeared on the cover of Forbes in 2015, and said his company would "be the highest return on investment endeavor ever taken up in the pharmaceutical industry."[32][39] Before new clinical trials began, he engineered an initial public offering (IPO) in Axovant.[32] Axovant became a "Wall Street darling" and raised $315 million in its IPO.[40] The company's market value initially soared to almost $3 billion, although at the time it only had eight employees, including Ramaswamy's brother and mother.[32] Ramaswamy took a massive payout after selling a portion of his shares in Roivant to Viking Global Investors.[32] He claimed more than $37 million in capital gains in tax year 2015.[32] Ramaswamy said his company would be the "Berkshire Hathaway of drug development"[3] and touted the drug as a "tremendous" opportunity that "could help millions" of patients, prompting some criticism that he was overpromising.[32]

In September 2017, the company announced that intepirdine had failed in its large clinical trial.[32][41] The company's value plunged; it lost 75% in one day and continued to decline afterward.[32] Shareholders who lost money included various institutional investors, such as the California State Teachers' Retirement System pension fund.[32] Ramaswamy was insulated from much of Axovant's losses because he held his stake through Roivant.[32][40] The company abandoned intepirdine.
How is this any different from that lady who conned a load of wealthy people out of that auto blood test box thing that never worked?
 
Status
Not open for further replies.

Welcome

Join the Everton conversation today.
Fewer ads, full access, completely free.

🛒 Visit Shop

Support Grand Old Team by checking out our latest Everton gear!
Back
Top